TNSN06071A1 - Use of modified cyclosporins for the treatment of hcv disorders - Google Patents

Use of modified cyclosporins for the treatment of hcv disorders

Info

Publication number
TNSN06071A1
TNSN06071A1 TNP2006000071A TNSN06071A TNSN06071A1 TN SN06071 A1 TNSN06071 A1 TN SN06071A1 TN P2006000071 A TNP2006000071 A TN P2006000071A TN SN06071 A TNSN06071 A TN SN06071A TN SN06071 A1 TNSN06071 A1 TN SN06071A1
Authority
TN
Tunisia
Prior art keywords
treatment
cyclosporins
hcv
disorders
modified
Prior art date
Application number
TNP2006000071A
Other languages
English (en)
French (fr)
Inventor
Kunitada Shimotohno
Koichi Watashi
Makoto Hijikata
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN06071A1 publication Critical patent/TNSN06071A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TNP2006000071A 2003-09-03 2006-03-02 Use of modified cyclosporins for the treatment of hcv disorders TNSN06071A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0320638.0A GB0320638D0 (en) 2003-09-03 2003-09-03 Organic compounds
PCT/EP2004/009804 WO2005021028A1 (en) 2003-09-03 2004-09-02 Use of modified cyclosporins for the treatment of hcv disorders

Publications (1)

Publication Number Publication Date
TNSN06071A1 true TNSN06071A1 (en) 2007-10-03

Family

ID=28686843

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000071A TNSN06071A1 (en) 2003-09-03 2006-03-02 Use of modified cyclosporins for the treatment of hcv disorders

Country Status (29)

Country Link
US (1) US7968518B2 (cg-RX-API-DMAC7.html)
EP (2) EP1663287B1 (cg-RX-API-DMAC7.html)
JP (1) JP4688806B2 (cg-RX-API-DMAC7.html)
KR (1) KR101116968B1 (cg-RX-API-DMAC7.html)
CN (1) CN1842343A (cg-RX-API-DMAC7.html)
AU (2) AU2004268382A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414062B8 (cg-RX-API-DMAC7.html)
CA (1) CA2537137C (cg-RX-API-DMAC7.html)
CY (1) CY1110506T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004022061D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663287T3 (cg-RX-API-DMAC7.html)
ES (1) ES2328361T3 (cg-RX-API-DMAC7.html)
GB (1) GB0320638D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20090535T1 (cg-RX-API-DMAC7.html)
IL (1) IL173909A (cg-RX-API-DMAC7.html)
IS (1) IS2917B (cg-RX-API-DMAC7.html)
MA (1) MA28032A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06002394A (cg-RX-API-DMAC7.html)
NO (1) NO20061479L (cg-RX-API-DMAC7.html)
NZ (1) NZ545495A (cg-RX-API-DMAC7.html)
PL (1) PL1663287T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663287E (cg-RX-API-DMAC7.html)
RU (1) RU2389501C2 (cg-RX-API-DMAC7.html)
SG (1) SG149063A1 (cg-RX-API-DMAC7.html)
SI (1) SI1663287T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN06071A1 (cg-RX-API-DMAC7.html)
TW (1) TWI342782B (cg-RX-API-DMAC7.html)
WO (1) WO2005021028A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200601550B (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001715A1 (fr) 1998-07-01 2000-01-13 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
GB0500020D0 (en) * 2005-01-04 2005-02-09 Novartis Ag Organic compounds
CA2573207C (en) 2004-07-14 2013-04-16 Novartis Ag Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
EP1809656A4 (en) 2004-09-29 2009-03-25 Amr Technology Inc CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
DK1802650T3 (da) * 2004-10-01 2012-02-06 Scynexis Inc 3-ether- og 3-thioether-substituerede cyklosporinderivater til behandling og forebyggelse af hepatitis C-infektion
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
NZ554412A (en) 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物
KR20070089954A (ko) * 2004-12-23 2007-09-04 노파르티스 아게 플라비비리대 치료용 화합물
MX2007016068A (es) * 2005-06-17 2008-03-10 Novartis Ag Uso de sanglifehrina en hcv.
US7754685B2 (en) * 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US8329658B2 (en) * 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
KR101273681B1 (ko) * 2005-10-26 2013-06-25 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
DK2023918T3 (da) 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
JP2009539292A (ja) * 2006-06-02 2009-11-12 ぺリション、クロード、アニー 活性電子の管理
US20100130408A1 (en) * 2006-10-12 2010-05-27 Motoyuki Kohjima Use of modified cyclosporins
WO2008069917A2 (en) * 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
RU2462262C2 (ru) 2007-01-04 2012-09-27 Дебиофарм С А Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха
JP5459545B2 (ja) * 2007-05-02 2014-04-02 アステラス製薬株式会社 新規環状ペプチド化合物
WO2009028418A1 (ja) 2007-08-24 2009-03-05 Sapporo Medical University シクロスポリンａ結合タンパク質
WO2010002428A2 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
MX2011001152A (es) * 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
JP5625910B2 (ja) * 2008-09-24 2014-11-19 アステラス製薬株式会社 ペプチド化合物およびその製造方法
WO2010052559A1 (en) * 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JP5780969B2 (ja) * 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
EP2391376A4 (en) * 2009-01-30 2012-08-01 Enanta Pharm Inc ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2624840A1 (en) 2010-10-05 2013-08-14 Novartis AG New treatments of hepatitis c virus infection
RU2013129824A (ru) 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
AU2012233644A1 (en) 2011-03-31 2013-09-12 Novartis Ag Alisporivir to treat Hepatitis C virus infection
BR112013024809A2 (pt) 2011-04-01 2016-09-06 Novartis Ag tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
PH12013502047A1 (en) 2011-04-13 2019-03-22 Debiopharm Int Sa Treatment of hepatitis c virus infection with alisporivir
WO2013045460A1 (en) 2011-09-27 2013-04-04 Novartis Ag Alisporivr for treatment of hepatis c virus infection
KR20150013152A (ko) 2012-05-07 2015-02-04 노파르티스 아게 알리스포리비르를 이용한 약동학적 조절
CN104487449A (zh) 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
CA2921961A1 (en) 2013-08-26 2015-03-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
EP4199937A1 (en) * 2020-08-24 2023-06-28 Nanomerics Ltd Viral inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
ES2095926T5 (es) 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1002792T3 (da) 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
WO2000001715A1 (fr) 1998-07-01 2000-01-13 Debiopharm S.A. Nouvelle cyclosporine ayant un profil d'activite ameliore
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2426381A1 (en) 2000-10-19 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Cell damage inhibitor
JP2002125683A (ja) * 2000-10-27 2002-05-08 Tokyoto Igaku Kenkyu Kiko インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ
IL157773A0 (en) 2001-03-26 2004-03-28 Novartis Ag 2-amino-propanol derivatives
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
CA2460640C (en) 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
US20030213603A1 (en) * 2002-05-14 2003-11-20 Fisher David B. Dual use extension apparatus for a tool
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
GB0313444D0 (en) 2003-06-11 2003-07-16 Midland Medical Technologies L Modular dysplasia cup
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
NZ554412A (en) 2004-10-01 2011-01-28 Debiopharm Sa Use of [D-MeAla]3-[EtVal]4-cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said [D-MeAla]3-[EtVal]4-cyclosporin
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物

Also Published As

Publication number Publication date
RU2006110533A (ru) 2007-10-10
KR20060132798A (ko) 2006-12-22
HK1091732A1 (en) 2007-01-26
BRPI0414062A (pt) 2006-10-24
BRPI0414062B1 (pt) 2019-06-25
TWI342782B (en) 2011-06-01
KR101116968B1 (ko) 2012-03-14
AU2004268382A1 (en) 2005-03-10
GB0320638D0 (en) 2003-10-01
EP1797892A1 (en) 2007-06-20
TW200524626A (en) 2005-08-01
US20070275884A1 (en) 2007-11-29
SI1663287T1 (sl) 2009-10-31
AU2008203031B2 (en) 2011-04-07
PL1663287T3 (pl) 2009-12-31
ES2328361T3 (es) 2009-11-12
US7968518B2 (en) 2011-06-28
EP1663287A1 (en) 2006-06-07
EP1663287B1 (en) 2009-07-15
EP1797892B1 (en) 2013-10-23
HRP20090535T1 (hr) 2009-11-30
BRPI0414062B8 (pt) 2021-05-25
CY1110506T1 (el) 2015-04-29
RU2389501C2 (ru) 2010-05-20
IS8371A (is) 2006-03-24
DE602004022061D1 (de) 2009-08-27
WO2005021028A1 (en) 2005-03-10
IL173909A (en) 2011-03-31
ZA200601550B (en) 2007-05-30
AU2008203031A1 (en) 2008-07-31
SG149063A1 (en) 2009-01-29
MA28032A1 (fr) 2006-07-03
CA2537137A1 (en) 2005-03-10
JP2007504260A (ja) 2007-03-01
JP4688806B2 (ja) 2011-05-25
MXPA06002394A (es) 2006-06-20
IL173909A0 (en) 2006-07-05
PT1663287E (pt) 2009-09-03
NZ545495A (en) 2010-01-29
NO20061479L (no) 2006-06-02
DK1663287T3 (da) 2009-11-09
CN1842343A (zh) 2006-10-04
CA2537137C (en) 2013-05-28
IS2917B (is) 2014-12-15

Similar Documents

Publication Publication Date Title
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TNSN07240A1 (en) Compounds for flaviviridae treatment
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
SG164376A1 (en) Hcv ns3 protease inhibitors
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
DK1419154T3 (da) Rapamycin-29-enoler
SG163517A1 (en) Antiviral compounds and methods
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2007150001A8 (en) Pyrro[1,2-b]pyridazinone compounds
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
TN2009000135A1 (en) Use of modified cyclosporins
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
WO2009067225A3 (en) Boceprevir derivatives for the treatment of hcv infections
UA90909C2 (en) Hcv ns3 protease inhibitors
PL1644403T3 (pl) Cytotoksyczne depsypeptydy
UA95990C2 (en) Hcv ns3 protease inhibitors
WO2010138889A8 (en) Peptides for the treatment of hcv infections
MX2008001548A (es) Compuestos antitumorales.
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.
WO2007081365A3 (en) Multiple antigenic agents and methods for using the same